The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans ... Specifically for COPD, our products have been on the market for more than 40 years.

Boehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev ... The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended ...

Boehringer Ingelheim has moved one of its top pipeline ... as symptoms are similar to other respiratory diseases, like chronic obstructive pulmonary disease (COPD) and asthma.

AMSTERDAM, BASEL, Switzerland and INGELHEIM, Germany, Jan. 9, 2025 /PRNewswire/ -- Boehringer Ingelheim and ... payments on net sales of resulting products.